Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

* Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).

* Treatment naive or have received prior standard therapy appropriate for tumor type and stage

* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

* Adequate organ function

* Primary central nervous system (CNS) tumors

* Active, untreated brain metastases

* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication

* History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy